

# 5

Fifth edition, 2015

# Medical eligibility criteria for contraceptive use

COCs Barrier methods IUDs Fertility awareness-based methods Lactational amenorrhoea Patch Female surgical sterilization Intrauterine devices CICs Coitus interruptus Copper IUD for emergency contraception POCs Patch Male surgical sterilization Ring ECPs

COCs Barrier methods IUDs Fertility awareness-based methods Lactational amenorrhoea Patch Female surgical sterilization Intrauterine devices CICs Coitus interruptus Copper IUD for emergency contraception POCs Patch Male surgical sterilization Ring ECPs

COCs Barrier methods IUDs Fertility awareness-based methods Lactational amenorrhoea Patch Female surgical sterilization Intrauterine devices CICs Coitus interruptus Copper IUD for emergency contraception POCs Patch Male surgical sterilization Ring ECPs

A WHO family planning cornerstone





# Medical eligibility criteria for contraceptive use

Fifth edition 2015



WHO Library Cataloguing-in-Publication Data

Medical eligibility criteria for contraceptive use -- 5th ed.

1. Contraception – methods. 2. Family Planning Services. 3. Eligibility Determination – standards. 4. Quality Assurance, Health Care. 5. Health Services Accessibility. I. World Health Organization.

ISBN 978 92 4 154915 8

(NLM classification: WP 630)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

## Table of contents

Acknowledgements .....	1
Guideline Development Group .....	1
Abbreviations .....	3
<b>EXECUTIVE SUMMARY .....</b>	<b>5</b>
Introduction .....	6
Guideline development methods .....	6
Summary of reviewed recommendations .....	6
<b>PART I. DEVELOPMENT OF THE MEDICAL ELIGIBILITY CRITERIA FOR CONTRACEPTIVE USE</b>	
Background .....	15
Methods .....	17
Dissemination and evaluation .....	21
Recommendations for combined hormonal contraceptives among breastfeeding women .....	28
Recommendations for combined hormonal contraceptives among postpartum women .....	34
Recommendations for combined hormonal contraceptives among women with superficial venous disorders .....	38
Recommendations for combined hormonal contraceptives among women with dyslipidaemias .....	42
Recommendations for progestogen-only contraceptives and levonorgestrel-releasing intrauterine devices among breastfeeding women .....	47
Recommendations for safety of depot medroxyprogesterone acetate delivered subcutaneously .....	61
Recommendations for safety of Sino-implant (II) .....	67
Recommendations for use of emergency contraceptive pills, including adding the condition of obesity and the new method, ulipristal acetate .....	72
Recommendations for intrauterine devices among women with increased risk for sexually transmitted infections .....	77
Recommendations for use of progesterone-releasing vaginal ring .....	79
Recommendations for use of hormonal contraception among women at high risk of HIV, women living with HIV, and women living with HIV using antiretroviral therapy .....	82
<b>PART II. USING THE RECOMMENDATIONS</b>	
Background .....	99
How to use this document .....	104
Using the categories in practice .....	105
Programmatic implications .....	106
Clients with special needs .....	106
Summary of changes within the MEC fifth edition .....	107
<b>TABLES</b>	
Combined hormonal contraceptives .....	111
Progestogen-only contraceptives .....	157
Emergency contraceptive pills .....	186
Intrauterine devices .....	189
Copper-bearing IUD for emergency contraception .....	211
Barrier methods .....	214
Fertility awareness-based methods .....	226
Lactational amenorrhoea method .....	229
Coitus interruptus .....	231
Female surgical sterilization .....	232
Male surgical sterilization .....	243
Summary table .....	248
<b>Annex 1. Declarations of interest .....</b>	<b>265</b>
<b>Annex 2. Systematic reviews .....</b>	<b>267</b>



## Acknowledgements

The World Health Organization (WHO) would like to thank the members of the Guideline Development Group and the Evidence Secretariat for their contributions throughout the development of these recommendations. WHO convened three consultations (13–16 May 2013, 9–12 March 2014 and 24–25 September 2014) to finalize the fifth edition of the Medical eligibility criteria for contraceptive use. All members of the Guideline Development Group and the Evidence Secretariat participated in at least one of the three consultations. WHO is very grateful for the suggestions provided by colleagues who peer-reviewed the earlier drafts of the guideline as members of the External Peer Review Group. The *names* of the participants in each group are listed below.

## Guideline Development Group

Richard Adanu (University of Ghana, Ghana), Eliana Amaral (State University of Campinas, Brazil), Jean-Jacques Amy (European Society for Contraception and Reproductive Health, Belgium), Sharon Cameron (University of Edinburgh, United Kingdom of Great Britain and Northern Ireland [United Kingdom]), Tsungai Chipato (University of Zimbabwe, Zimbabwe), Roger Chou (Oregon Health Sciences University, United States of America [USA]), Jacqueline Conard (Hôpital Universitaire de Paris – Hôtel Dieu, France), Maria del Carmen Cravioto (National Institute of Nutrition Salvador Zubiran, Mexico), Marc Dhont (Ghent University Hospital, Belgium), Alison Edelman (Oregon Health Sciences University, USA), Faysel El-Kak (American University of Beirut, Lebanon), Mohammed Eslami (Ministry of Health and Education, Islamic Republic of Iran), Karima Gholbzouri (Ministry of Health, Morocco), Gathari Gichuhi (Jhpiego, Kenya), Anna Glasier (University of Edinburgh, United Kingdom), Andy Gray (University of KwaZulu-Natal, South Africa), Philip Hannaford (University of Aberdeen, United Kingdom), Caitlin Kennedy (Johns Hopkins University, USA), Pisake Lumbiganon (Khon Kaen University, Thailand), Francesca Martínez (Institut Universitari Dexeus, Spain), Olav Meirik (Instituto Chileno de Medicina Reproductiva, Chile), Suneeta Mittal (Fortis Memorial Research Institute, India), Herbert Peterson (University of North Carolina, USA), Maria Ascuncion Silvestre (University of the Philippines, the Philippines), Regine Sitruk-Ware (Population Council, USA), Marja-Riitta Taskinen (University of Helsinki, Finland), Tran Son Thach (University of Adelaide, Australia), Carolyn Westhoff (Columbia University, USA), Wu Shangchun (National Research Institute for Family Planning, China).

## Evidence Secretariat

Erin Berry-Bibee (United States Centers for Disease Control and Prevention [CDC]), Remy Coeytaux (Duke University, USA), Kathryn Curtis (CDC), Tara Jatlaoui (CDC), Kavita Nanda (FHI 360), Chelsea Polis (United States Agency for International Development [USAID]), Halley Riley (CDC), Naomi Tepper (CDC), Rachel Peragallo Urrutia (University of North Carolina, USA).

## Partners

- European Medicines Agency (EMA) – Peter Arlett, Corinne de Vries, Julie Williams
- International Confederation of Midwives (ICM) – Maria Papadopoulou
- International Federation of Gynecology and Obstetrics (FIGO) – Hamid Rushwan
- United Nations Population Fund (UNFPA) – Sennen Hounton
- United States Food and Drug Administration (FDA) – Lisa Soule
- United States National Institutes of Health (NIH) – Alicia Armstrong, Trent MacKay
- USAID – Patricia MacDonald, James Shelton

## External Peer Review Group

Anna Altshuler (Stanford University, USA), Parnian Andalib (Ministry of Education, Islamic Republic of Iran), Paul Blumenthal (Stanford University, USA), Vivian Brache (Profamilia, Dominican Republic), Caroline Phiri Chibawe (Ministry of Health, Zambia), Roy Jacobstein (EngenderHealth, USA), Helle Karro (Tartu University, Estonia), Vinit Sharma (UNFPA Asia Pacific Regional Office, Thailand), Bulbul Sood (Jhpiego, India), Elizabeth Sullivan (University of Sydney, Australia), Nonkosi Tiale (UNFPA, Lesotho), Ilze Viberga (University of Latvia, Latvia), Eliya Zulu (African Institute for Development Policy, Kenya).

## WHO Secretariat

### WHO headquarters

Department of Essential Medicines and Health Products  
– Nicola Magrini, Lembit Ragu

Department of HIV – Rachel Baggaley

Department of Management of Noncommunicable Diseases, Disability, Violence & Injury Prevention  
– Maria Alarcos Cieza Moreno

Department of Maternal, Newborn, Child and Adolescent Health  
– Nigel Rollins

Department of Reproductive Health and Research – Moazzam Ali, Keri Barnett-Howell (volunteer), Venkatraman Chandra-Mouli, Shannon Carr (volunteer), Monica Dragoman, Mario Festin, Mary Lyn Gaffield, Rajat Khosla, Caron Kim, Sharon Phillips, Maria Rodriguez, Theresa Ryle, Petrus Steyn, Marleen Temmerman, Teodora Wi

### WHO regional offices

WHO Regional Office for Africa – Léopold Ouedraogo

WHO Regional Office for the Eastern Mediterranean – Ramez Mahaini (unable to attend)

WHO Regional Office for Europe – Gunta Lazdane

WHO Regional Office for the Americas (Pan American Health Organization) – Suzanne Serruya

WHO Regional Office for South-East Asia – Arvind Mathur

WHO Regional Office for the Western Pacific – Wen Chunmei

### Overall coordination

WHO Department of Reproductive Health and Research – Mary Lyn Gaffield. Theresa Ryle provided coordination and logistic support.

### Writing

The first draft of the guideline was written by Erin Berry-Bibee, Kathryn Curtis, Monica Dragoman, Mary Lyn Gaffield, Tara Jatlaoui, Caron Kim, Halley Riley and Naomi Tepper. Drafts were reviewed and input was provided by members of the Guideline Development Group, peer reviewers

### Funding

The development of this guideline was financially supported by the National Institutes of Health (NIH) and United States Agency for International Development (USAID).

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27551](https://www.yunbaogao.cn/report/index/report?reportId=5_27551)

